| 32.035 -2.055 (-6.03%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.95 | 1-year : | 47.83 |
| Resists | First : | 35.06 | Second : | 40.95 |
| Pivot price | 32.02 |
|||
| Supports | First : | 30.69 | Second : | 28 |
| MAs | MA(5) : | 33.41 |
MA(20) : | 32.17 |
| MA(100) : | 24.89  |
MA(250) : | 20.1 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 79.2 |
D(3) : | 86.8 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 35.31 | Low : | 10.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SYRE ] has closed below upper band by 49.8%. Bollinger Bands are 4.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.5 - 34.67 | 34.67 - 34.78 |
| Low: | 31.38 - 31.6 | 31.6 - 31.74 |
| Close: | 31.72 - 32.05 | 32.05 - 32.26 |
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Fri, 23 Jan 2026
Spyre’s new commercial chief granted 108K stock options at $34.09 - Stock Titan
Fri, 23 Jan 2026
Spyre Therapeutics Announces Grants of Inducement Awards - Yahoo Finance Singapore
Thu, 15 Jan 2026
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating - Finviz
Wed, 14 Jan 2026
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% Higher - What's Next? - MarketBeat
Tue, 13 Jan 2026
Spyre Therapeutics (SYRE) Valuation After New Trial Milestones And Commercial Leadership Appointment - simplywall.st
Mon, 12 Jan 2026
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 84.5 (%) |
| Shares Short | 11,640 (K) |
| Shares Short P.Month | 11,160 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.94 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.3 % |
| Return on Equity (ttm) | -38.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.29 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -162 (M) |
| Levered Free Cash Flow | -126 (M) |
| PE Ratio | -24.27 |
| PEG Ratio | 0 |
| Price to Book value | 6.47 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|